Status and phase
Conditions
Treatments
About
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
Full description
This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed iNO compared to placebo in subjects with COVID-19 who are hospitalized and require supplemental oxygen without assisted ventilation. Subjects will be randomized to receive placebo or iNO125 mcg/kg ideal body weight (IBW)/hour 24 hours daily up to 14 days or until resolution or discharge.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Signed informed consent
At least 18 years old
Subjects must be hospitalized and have the following:
Female subjects must have a negative pregnancy test
Willing and able to comply with the treatment schedule and study procedures
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
191 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal